☰

Nathan E. Standifer, Ph.D. - Publications

Affiliations: 
2003 The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States 
Area:
Immunology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature Communications. 15: 1700. PMID 38402224 DOI: 10.1038/s41467-024-45996-4  0.316
2023 Song X, Kelley RK, Green M, Standifer N, Lim K, Zhou D, Dunyak J, Negro A, Kurland JF, Ren S, Khan AA, Gibbs M, Abou-Alfa GK. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients With Unresectable Hepatocellular Carcinoma. Clinical Pharmacology and Therapeutics. PMID 37422678 DOI: 10.1002/cpt.2992  0.38
2023 Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Ramakrishnan Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, ... ... Standifer N, et al. Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36826995 DOI: 10.1158/1078-0432.CCR-22-2955  0.513
2022 He JZ, Wang H, Lim K, Ren S, Rollins F, Vallaster M, Wong R, Stebbings R, Standifer N, Keefe R, Phipps A, Gibbs M. A Consideration of Fixed Dosing Versus Body Size-Based Dosing Strategies for Chimeric Antigen Receptor T-Cell Therapies. Clinical Pharmacology in Drug Development. PMID 36094760 DOI: 10.1002/cpdd.1171  0.316
2021 Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunology, Immunotherapy : Cii. PMID 33420629 DOI: 10.1007/s00262-020-02833-z  0.401
2012 Hondowicz BD, Schwedhelm KV, Kas A, Tasch MA, Rawlings C, Ramchurren N, McIntosh M, D'Amico LA, Sanda S, Standifer NE, Shendure J, Stone B. Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. Plos One. 7: e29949. PMID 22253836 DOI: 10.1371/Journal.Pone.0029949  0.429
2011 Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proceedings of the National Academy of Sciences of the United States of America. 108: 7938-43. PMID 21518860 DOI: 10.1073/Pnas.1017360108  0.41
2010 Stacy S, Williams EL, Standifer NE, Pasquali A, Krolick KA, Infante AJ, Kraig E. Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 184: 6067-75. PMID 20435934 DOI: 10.4049/Jimmunol.0901618  0.61
2010 Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, Diamantopoulos S, Standifer N, Geubtner K, Falk BA, Ichii H, Takahashi H, Snowhite I, Chen Z, Mendez A, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 59: 947-57. PMID 20086230 DOI: 10.2337/Db09-0498  0.508
2010 Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. Journal of Virology. 84: 3312-9. PMID 20071564 DOI: 10.1128/Jvi.02226-09  0.358
2010 Hondowicz B, Schwedhelm K, Kas A, Tasch M, Ramchurren N, Standifer N, Sanda S, Rawlings C, Shendure J, Stone B. High-throughput Screening for CD8+ T Cell Epitopes Targeted in Type 1 Diabetes Clinical Immunology. 135: S19. DOI: 10.1016/J.Clim.2010.03.063  0.31
2009 Standifer NE, Burwell EA, Gersuk VH, Greenbaum CJ, Nepom GT. Changes in autoreactive T cell avidity during type 1 diabetes development. Clinical Immunology (Orlando, Fla.). 132: 312-20. PMID 19482555 DOI: 10.1016/j.clim.2009.04.013  0.5
2009 Standifer N, Burwell E, Nepom G. S.48. Longitudinal Dynamics of CD4+T Cell Responses to an Insulin Peptide in Healthy, Autoantibody-positive and Type 1 Diabetic Subjects Clinical Immunology. 131: S145-S146. DOI: 10.1016/J.Clim.2009.03.429  0.326
2008 Standifer N, Nepom G. OR.9. A Shift in Autoreactive CD4 T Cell Avidity Preceding Diagnosis with Type 1 Diabetes is Correlated with the Outgrowth of Distinct T Cell Clonotypes Clinical Immunology. 127: S7. DOI: 10.1016/J.Clim.2008.03.014  0.42
2007 Standifer NE, Stacy S, Kraig E, Infante AJ. Discrete T cell populations with specificity for a neo-self-antigen bear distinct imprints of tolerance. Journal of Immunology (Baltimore, Md. : 1950). 178: 3544-50. PMID 17339450 DOI: 10.4049/Jimmunol.178.6.3544  0.634
2007 Standifer N, Nepom G. Evidence for an Increase in the Functional Avidity of the GAD-reactive CD4+ T Cell Population Prior to Diabetes Onset Clinical Immunology. 123: S67. DOI: 10.1016/J.Clim.2007.03.369  0.351
2006 Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 103: 17414-9. PMID 17088564 DOI: 10.1073/Pnas.0605136103  0.461
2006 Ouyang Q, Standifer NE, Qin H, Gottlieb P, Verchere CB, Nepom GT, Tan R, Panagiotopoulos C. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes. 55: 3068-74. PMID 17065344 DOI: 10.2337/db06-0065  0.338
2006 Reichstetter S, Standifer NE, Geubtner KA, Liu AW, Agar SL, Kwok WW. Cytotoxic herpes simplex type 2-specific, DQ0602-restricted CD4 T+-cell clones show alloreactivity to DQ0601. Immunology. 117: 350-7. PMID 16476054 DOI: 10.1111/j.1365-2567.2005.02308.x  0.436
2006 Stone B, Graves S, Kas A, Ford A, Standifer N, Rawlings C, Rosinski S, Masewicz S, Olson M, Storb RF. Direct Genotyping of Coding Non-Synonymous SNPs for Identification of Novel Minor Histocompatibility Antigens. Blood. 108: 3237-3237. DOI: 10.1182/Blood.V108.11.3237.3237  0.321
2003 Standifer NE, Kraig E, Infante AJ. A hierarchy of T cell receptor motifs determines responsiveness to the immunodominant epitope in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology. 145: 68-76. PMID 14644032 DOI: 10.1016/J.Jneuroim.2003.09.007  0.638
1996 Kraig E, Pierce JL, Clarkin KZ, Standifer NE, Currier P, Wall KA, Infante AJ. Restricted T cell receptor repertoire for acetylcholine receptor in murine myasthenia gravis. Journal of Neuroimmunology. 71: 87-95. PMID 8982107 DOI: 10.1016/S0165-5728(96)00151-8  0.61
Show low-probability matches.